All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

  TRANSLATE

The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

BMT Tandem Meetings | Rituximab first-line therapy for chronic GvHD

By Devona Williams

Share:

Feb 23, 2018


Data was presented at the 2018 BMT Tandem Meetings in Salt Lake City, Utah regarding rituximab as first-line treatment in cGVHD. The study was led by Connie Sizemore of Northside Hospital in Atlanta, Georgia. Patients in the study continued to receive standard immunosuppression agents, but only short course steroid therapy was permitted. 

Key Findings:

  • N = 95 patients
  • Median age = 55 years (range 24 to 75 years)
  • NIH cGVHD grading
    • Mild = 6%
    • Moderate = 42%
    • Severe = 52%
  • Median number of GVHD sites involved = 4 (range 1 to 7)
  • GVHD sites involved
    • Mouth = 84%
    • Skin = 77%
    • Eyes = 74%
    • Upper GI = 44%
    • Liver = 40%
  • Quiescence and taper of immunosuppression = 72.6%
  • Three-year resolution of cGVHD = 71%
  • Two-year overall survival = 80%
  • Two-year non-relapse mortality = 15%
  • Overall incidence of recurrent GVHD = 15%

This study shows that rituximab is a promising therapy choice for providing favorable clinical outcomes, while minimizing adverse events of high dose steroid therapy. Further study is warranted in a larger population, as well as determination of prognostic factors predicting which patients are at highest risk of GVHD relapse with rituximab therapy.

 

References